Investigational agents in metastatic basal cell carcinoma: focus on vismodegib

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib.

Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Erivedge™) is a novel first-in-human, first-in class, orally bio-available Hedgehog pathway signaling inhibitor of the G-protein coupled receptor-like protein smoothened (SMO) which was approved in the United States on January 2012. This signaling pathway is involved in the carcinogenesis of several ...

Vismodegib (erivedge) for advanced Basal cell carcinoma.

Vismodegib (Erivedge) for advanced basal cell carcinoma.

Focus on Basal Cell Carcinoma

Nonmelanoma skin cancers (NMSCs), which include basal and squamous cell cancers are the most common human cancers. BCCs have a relatively low metastatic rate and slow growth and are frequently underreported. Whilst there is a definite role of sunexposure in the pathogenesis of BCC, several additional complex genotypic, phenotypic and environmental factors are contributory. The high prevalence a...

Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma

© 2014 Harborside Press® Skin cancer is the most common cancer type in the United States, affecting more than 3 million people nationally (Cirrone & Harris, 2012). Basal cell carcinoma (BCC) and squamous cell carcinoma are the two main types of nonmelanoma skin cancer, while the more serious form, melanoma, is in its own category. An estimated 80% of nonmelanoma skin cancers are BCCs (Sekulic e...

Metastatic Basal Cell Carcinoma